Pemetrexed-induced lipodermatosclerosis: clinical course and management of a rare cutaneous toxicity

We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity t...

Full description

Saved in:

Bibliographic Details
Published in:	Current problems in cancer. Case reports Vol. 19; p. 100386
Main Authors:	Kahlon, Navkirat, Vallepu, Shirisha, Gowda, Anusha Manje, Baddam, Sujatha
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01.09.2025 Elsevier
Subjects:	Chemo side effect Drug toxicity Hematology, Oncology, and Palliative Medicine Lung cancer treatment Rare side effect Chemo side effect Lung cancer treatment Drug toxicity Rare side effect
ISSN:	2666-6219, 2666-6219
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We present the case of a 67-year-old male with stage IV lung adenocarcinoma who developed pemetrexed-induced lipodermatosclerosis (LDS) and a flare of polymyalgia rheumatica (PMR) during chemotherapy treatment. Initially misdiagnosed as cellulitis, the patient experienced progressive skin toxicity that was ultimately recognized as LDS, associated with pemetrexed. The management of PMR flares and LDS was complex, requiring steroid therapy adjustments and the introduction of pentoxifylline. This case highlights the need for awareness of chemotherapy-induced skin toxicity and the challenges of managing underlying autoimmune conditions in cancer treatment.
ISSN:	2666-6219 2666-6219
DOI:	10.1016/j.cpccr.2025.100386